Cloud-Clone antibodies appear in Nature, Cancer Cell and Advanced Science studies

Cloud-Clone Corp. says its antibodies were used in three 2026 studies published in Nature, Cancer Cell and Advanced Science across metabolism, liver-cancer immunology and gut-brain-axis research. The company frames the papers as evidence that its reagents can meet top-tier validation standards in high-stakes biomedical work.

Why it matters: - Three independent research teams used Cloud-Clone antibodies in studies that cleared peer review in Nature, Cancer Cell and Advanced Science. - The papers span metabolism, oncology immunology and gut-brain-axis research. - The publications are being presented as evidence that Cloud-Clone reagents can perform in high-stakes workflows that require strong specificity, sensitivity and consistency.

What happened: - Researchers in the United States, China and India published three separate papers in 2026 that used Cloud-Clone antibodies as key validation tools. - A May 27, 2026 Nature paper from the Wisconsin Institute for Research and the University of Pittsburgh used a Cloud-Clone CRAT polyclonal antibody, PAC400Mu01. - A Cancer Cell study from Professor Kuang Ming’s team at the First Affiliated Hospital of Sun Yat-sen University used a Cloud-Clone C3a polyclonal antibody, PAA387Hu01. - An Advanced Science paper from the Institute of Nano Science and Technology, India, used 14 Cloud-Clone polyclonal antibodies in parallel IHC profiling.

The details: - The Nature study linked α-ketoglutarate to de novo carnitine biosynthesis, histone acetylation changes and reduced homologous-recombination repair capacity in tumor cells, contributing to resistance against chemotherapy and PARP inhibitors. - The research team used the CRAT antibody for western blot verification of knockdown efficiency and for monitoring histone-acetylation profiles. - The Cancer Cell paper examined HBV-associated recurrent hepatocellular carcinoma and described a B-cell-driven response in tumor tertiary lymphoid structures after PD-1 blockade. - The study used C3a as a readout for complement activation in Type-B patient tumors and applied the Cloud-Clone antibody for immunohistochemistry on clinical tissue sections. - The Advanced Science paper studied an oral β-gluc-encapsulated nanomedicine, βG@Apr-WPG NMs, in ulcerative colitis and related neuropsychiatric symptoms. - That study used 14 Cloud-Clone antibodies to assess inflammatory signaling, intestinal-barrier markers and immune-metabolism markers, including TLR4, STING, NF-κB, NLRP3, MUC2, Occludin, ZO-1, Claudin, CD8 and AMPK. - The company says the antibody panel produced high-signal-to-noise staining and stable performance across the assays. - By the end of 2025, Cloud-Clone reagents had been cited in more than 42,000 SCI-indexed publications, including over 350 papers in elite journals such as Nature, Science and Cell. - Cloud-Clone says it now operates polyclonal-antibody, monoclonal-antibody and recombinant-antibody platforms. - The company says its in-house native antibody repository holds more than 27,000 entries. - Cloud-Clone says compatible conjugation supports more than 30 reporter labels and produces nearly one million derived antibody resources across tens of thousands of research targets. - The company says its validation workflow combines internal functional testing, third-party verification and literature-based evidence. - Cloud-Clone says its antibodies are assessed across western blot, IHC, immunofluorescence and flow cytometry for specificity, sensitivity and batch-to-batch stability. - For more information, see the company’s announcement.

Between the lines: - The release uses top-journal placements to argue that Chinese reagent makers are closing the performance gap with established international suppliers. - The three studies are different enough to test different product qualities: single-target specificity in Nature, clinical-tissue staining in Cancer Cell and multi-antibody consistency in Advanced Science. - The claims about broad market momentum are promotional, but the journal placements themselves give the company a visible credibility signal.

What's next: - Cloud-Clone is likely to keep using high-impact publications as proof points for broader adoption in the global research market. - More independent validations in clinical and multi-target workflows would strengthen the company’s case for parity with premium reagent brands.

The bottom line: - Cloud-Clone is positioning three 2026 journal appearances as proof that its antibodies can hold up in demanding, publishable science.